Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Lymphoma, Mantle-Cell 5Hodgkin Disease 5Lymphoma 4Recurrence 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Uveal Melanoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Glioblastoma 2Burkitt Lymphoma 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Pediatric Brain Tumor 1Pancreatic Neoplasms 1Opsoclonus-Myoclonus Syndrome 1Oligodendroglioma 1Neuromyelitis Optica 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3romidepsin 2pembrolizumab 2etoposide phosphate 2duvelisib 2Melphalan 2Brentuximab Vedotin 2Azacitidine 210-propargyl-10-deazaaminopterin 2tazemetostat 1sodium-iodide symporter 1ruxolitinib 1prednylidene 1glofitamab 1fludarabine phosphate 1fludarabine 1deltacortene 1cemiplimab 1brincidofovir 1belinostat 1X-Rays 1Whole-Body Irradiation 1Valganciclovir 1Therapeutics 1Tacrolimus 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × Carmustine × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡